Title:
AFFINITY MATURED ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
Document Type and Number:
Japanese Patent JP2022119907
Kind Code:
A
Abstract:
To provide more effective therapies for cutaneous T-cell lymphoma (CTCL).SOLUTION: The present invention provides affinity matured humanized monoclonal antibodies, bispecific antibodies, antibody conjugates and fusion proteins that bind to the chemokine receptor CCR4. The antibodies are derived from mAb 1567 and recognize the same epitope. Binding of the antibodies to CCR4 inhibits ligand-mediated activity and is used to treat symptoms of cancer. Moreover, the antibodies are used in combination with vaccines to suppress the activity of regulatory T cells.SELECTED DRAWING: Figure 1
Inventors:
WAYNE A MARASCO
SUI JIANHUA
ZHU QUAN
CHANG DE-KUAN
SUI JIANHUA
ZHU QUAN
CHANG DE-KUAN
Application Number:
JP2022086515A
Publication Date:
August 17, 2022
Filing Date:
May 27, 2022
Export Citation:
Assignee:
DANA FARBER CANCER INST INC
International Classes:
C12N15/13; A61K39/00; A61K39/395; A61K47/68; A61P31/04; A61P31/12; A61P35/00; A61P35/02; A61P37/04; A61P37/06; A61P43/00; C07K16/28; C07K16/46; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/0783; C12N5/10; C12N15/63
Attorney, Agent or Firm:
Shimizu Hatsushi
Masao Haruna
Hirotaka Yamaguchi
Shun Jinbe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Masato Ozeki
Kazuya Kawamoto
Masao Haruna
Hirotaka Yamaguchi
Shun Jinbe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Masato Ozeki
Kazuya Kawamoto